Poorly Designed Pulse Oximeters Endangered Black and Latino Patients During Pandemic, Study Finds

Many Black and Latino patients received delayed care for COVID-19 due to poorly designed pulse oximeters, researchers warn

People of color often fail to receive life-saving treatments for COVID-19, because pulse oximeters used to monitor their vitals do not accurately read darker skin tones, sometimes resulting in a failure to diagnose the illness, according to the findings of a new study.

Pulse oximeters are used to read oxygen levels in hospital and clinical settings. However, researchers from Johns Hopkins University School of Medicine warn that the devices are flawed, and provide inaccurate readings for Black, Latino and Asian Americans compared to white patients. The findings were published May 31, in the journal JAMA Internal Medicine.

The inaccurate readings make it difficult for people of color to receive proper medical attention, and at times, life-saving medical attention, during the COVID-19 pandemic. The devices, ubiquitous throughout the medical system, can make patients of color seem healthier than they really are, the study warns.

The researchers conducted a retrospective study of 7,100 patients with COVID-19 from five medical centers and community hospitals in the Johns Hopkins Health System. They compared data of patients’ oxygen saturation levels by using pulse oximetry and arterial blood gas, a much more invasive approach.

The data indicated pulse oximetry overestimated blood oxygen levels among Asian, Black, and Hispanic patients compared with white patients. Pulse oximetry failed to identify Black and Latino patients who meet qualifications to receive COVID-19 therapy based on their oxygen levels. This led to significant delays in treatment.

Overall, 30% of Asian patients, 29% of Black patients and 30% of Latino patients suffered hypoxia, or a dangerously low level of oxygen in the blood, which is a sign of breathing or circulation problems, especially important during the pandemic. Comparatively, only 17% of white patients suffered hypoxia.

Black patients had a 29% increased risk of not receiving timely treatment. Among Latinos, their risk was 23% compared to white patients. Blood oximeters overestimated blood oxygen levels by about 2% among Asian patients, 1% in Black patients and 1% among Latino patients.

Among 451 patients, 23% never had their eligibility for treatment recognized based on blood oximeter levels. Of those patients, 54% were Black. On average, Black patients often had to wait one hour or more compared to white patients to have treatment eligibility recognized.

“The results of this cohort study suggest that racial and ethnic biases in pulse oximetry accuracy were associated with greater occult hypoxemia in Asian, Black, and non-Black Hispanic patients with COVID-19, which was associated with significantly delayed or unrecognized eligibility for COVID-19 therapies among Black and Hispanic patients,” the researchers determined. “This disparity may contribute to worse outcomes among Black and Hispanic patients with COVID-19.”

Did You Know?

AT&T Data Breach Impacts Millions of Customers

More than 73 million customers of AT&T may have had their names, addresses, phone numbers, Social Security numbers and other information released on the dark web due to a massive AT&T data breach. Lawsuits are being pursued to obtain financial compensation.

Learn More

Pulse oximeters are devices placed on the patient’s finger to detect a person’s oxygen levels by the way the light is absorbed by the skin. Pulse oximetry helps with triage and treatment decisions for many medical conditions, but especially for COVID-19.

According to previous research, darker skin and even dark nail polish can skew the reading. Reports of disparities among patients of color date back to the 1990s, yet nothing has changed.

During the pandemic pulse oximeters have been extremely important in helping to determine the severity of COVID, but patients of color would receive treatment at much later times based on the flawed technology. Researchers warn the device is necessary for the medical community, but the technology must be updated to properly serve all patients, including those of color.


  • paulJanuary 26, 2023 at 3:53 pm


  • DawnJuly 9, 2022 at 8:16 pm

    Is there a class action lawsuit for this? I had blood clots and was told I was fine because my OX level was 97. I showed her a picture of my home ox and it said 89 but they ignored it. It should not be used if it not for all patients. Period

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Gardasil Vaccine Lawsuits Being Prepared For Early Test Trials in Federal MDL
Gardasil Vaccine Lawsuits Being Prepared For Early Test Trials in Federal MDL (Posted yesterday)

In advance of a a conference this week, lawyers report that progress is being made to prepare a group of federal Gardasil vaccine lawsuits for early test trials, to help gauge how juries may respond to certain evidence and testimony that will be repeated throughout the litigation.

Enfamil Lawsuit Claims Preemie Developed NEC After Being Fed Cow's Milk-Based Infant Formula
Enfamil Lawsuit Claims Preemie Developed NEC After Being Fed Cow's Milk-Based Infant Formula (Posted 2 days ago)

Cow's milk-based infant formula products are dangerous for premature infants, according to a mother's recent Enfamil lawsuit, filed after her newborn developed necrotizing enterocolitis and suffered through surgery and continuing negative health effects.

Ozempic MDL Lawsuits Reassigned To New Judge For Further Pretrial Proceedings
Ozempic MDL Lawsuits Reassigned To New Judge For Further Pretrial Proceedings (Posted 5 days ago)

All lawsuits over Ozempic, Mounjaro, Wegovy and other GLP-1 RA drugs to U.S. District Judge Karen S. Marston, following the death last month of the judge originally appointed to preside over all claims involving stomach paralysis and other gastrointestinal injuries.